Literature DB >> 36199702

Von Willebrand Factor Multimer Analysis by Low Resolution SDS-Agarose Gel Electrophoresis.

Herbert Gritsch1, Margit Stimpfl1, Peter L Turecek2.   

Abstract

Von Willebrand factor (VWF) is a complex glycoprotein found in plasma, composed of disulfide-bond-linked multimers with apparent molecular weights between 500 kDa and 20,000 kDa. After release of VWF from storage granules, it is cleaved in flowing blood by the specific metalloproteinase ADAMTS13, resulting in a highly characteristic cleavage pattern and structure. As the structure of VWF multimers determines diagnosis of von Willebrand disease, which has different sub-types with different multimer- and cleavage patterns, VWF analysis is performed using low-resolution horizontal SDS-agarose gel electrophoresis. However, almost every laboratory uses a different protocol, and all experimental details are rarely, if at all, described. Therefore, the results from similar methods may be substantially different. Here, we present a detailed description of a validated VWF multimer method that we have developed. It has been successfully used for over more than 20 years in quality control of recombinant and plasma-derived VWF drug products, and in preclinical and clinical studies with VWF drug candidates. As most of the published methods, it enables visualization of VWF multimers separated by electrophoresis by immunostaining with a polyclonal anti-human VWF antibody followed by a secondary antibody coupled to alkaline phosphatase. VWF appears as a series of regularly spaced bands on the low and middle molecular weight range of the gel, with an unresolved zone in the high molecular weight (HMW) range, where ultra-large multimers are found. An example is shown below. This low-resolution agarose gel electrophoresis allows the determination of the number of VWF multimers with high reproducibility. Graphical abstract: Example of electrophoretic analysis of multimer structure of four batches of a recombinant VWF drug substance.
Copyright © 2022 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Multimers; VWD; VWF; VWF Immunostaining; Von Willebrand Disease; Von Willebrand Factor

Year:  2022        PMID: 36199702      PMCID: PMC9486687          DOI: 10.21769/BioProtoc.4495

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  13 in total

1.  In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease.

Authors:  P L Turecek; H Gritsch; L Pichler; W Auer; B Fischer; A Mitterer; W Mundt; U Schlokat; F Dorner; H J Brinkman; J A van Mourik; H P Schwarz
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

Review 2.  Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor.

Authors:  Flora Peyvandi; Peter Kouides; Peter L Turecek; Edward Dow; Erik Berntorp
Journal:  Blood Rev       Date:  2019-04-03       Impact factor: 8.250

3.  Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond.

Authors:  Emmanuel J Favaloro; Leonardo Pasalic; Brandon Henry; Giuseppe Lippi
Journal:  Am J Hematol       Date:  2021-05-15       Impact factor: 10.047

Review 4.  von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein.

Authors:  R Schneppenheim; U Budde
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

Review 5.  Structure and function of a recombinant von Willebrand factor drug candidate.

Authors:  Peter L Turecek; Gerald Schrenk; Hanspeter Rottensteiner; Katalin Varadi; Edouard Bevers; Peter Lenting; Nicola Ilk; Uwe B Sleytr; Hartmut J Ehrlich; Hans Peter Schwarz
Journal:  Semin Thromb Hemost       Date:  2010-07-15       Impact factor: 4.180

6.  Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease.

Authors:  D Meyer; B Obert; G Pietu; J M Lavergne; T S Zimmerman
Journal:  J Lab Clin Med       Date:  1980-04

Review 7.  von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.

Authors:  David Lillicrap
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

8.  The role of ultralarge multimers in recombinant human von Willebrand factor - a review of physico-and biochemical studies and findings in in vivo models and in humans with von Willebrand disease.

Authors:  Peter L Turecek; Michael Spannagl; Thorsten Kragh; Guenter Allmaier; Marietta Turecek; Gerald Schrenk; Herbert Gritsch; Ortrun Obermann-Slupetzky; Bruce M Ewenstein; Leonard A Valentino
Journal:  Hamostaseologie       Date:  2017-12-28       Impact factor: 1.778

Review 9.  Of von Willebrand factor and platelets.

Authors:  Marijke Bryckaert; Jean-Philippe Rosa; Cécile V Denis; Peter J Lenting
Journal:  Cell Mol Life Sci       Date:  2014-10-09       Impact factor: 9.261

Review 10.  Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy.

Authors:  Ryan Seth; Thomas A J McKinnon; X Frank Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-12-10       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.